Posted Fri, Jun, 21,2013
Published today in Clinical Medicine Reviews in Vascular Health is a new review by Alex Y. Tan and Michael A. Rosenberg. Read more about this paper below:
Title
Lowering the Risk for Thrombus and Stroke in Atrial Fibrillation Patients: Will Dabigatran Replace Warfarin?
Abstract
The use of oral anticoagulation to reduce stroke risk from thromboembolism has become the cornerstone of management of atrial fibrillation (AF). Dabigatran is a direct thrombin inhibitor which, in contrast to warfarin, does not require regular blood draws for monitoring effect. Randomized controlled studies suggest that dabigatran may be more effective than warfarin at higher doses, without an increased bleeding risk, and equally effective at lower doses, with lower bleeding risk. With these apparent advantages comes a higher cost, and limited use in patients with underlying renal or liver disease. In addition, the inability to measure anticoagulant effect, as with warfarin, presents drawback for clinical use of dabigatran. In this review, we discuss the mechanisms of action, clinical effect, and place in therapy of dabigatran as a possible replacement for warfarin.
Click here to learn more about the article, download it and comment
Posted in: Articles Published
News Categories
Thu 08 Oct, 2015
Published This Week (5th - 9th October)Thu 08 Oct, 2015
Biomarker Insights Paper Endorsed by Editor in ChiefWed 07 Oct, 2015
Interview with Professor Jamie DaviesPublishing in the International Journal of Tryptophan Research was a smooth and efficient process. I was kept extremely well informed of the progress of my publication and the review process was thorough, positive and formative. I look forward to repeating the experience in the near future.
Facebook Google+ Twitter
Pinterest Tumblr YouTube